65,437 trials
Multiple Sclerosis · Spasticity, Muscle
Primary: Number of Participants With Adverse Events, Change in Vital Signs, Clinical Laboratory Test Results, 12-lead ECGs, USP Questionnaire, and C-SSRS Results — 276 Participants
Autism Spectrum Disorder
Primary: Ekman-60 Faces Test — 38.56; 32.03 score on a scale
Multiple Sclerosis · Spasticity, Muscle
Primary: Change From Baseline in Total Numeric-transformed Modified Ashworth Scale Score of the Most Affected Limb (TNmAS-MAL) — -1.7; -2.0; -1.4 units on a scale
Pain · Local Anesthesia for Peripheral Intravenous Catheterization
Primary: Pain Score Following Anesthetic Administration — 2.81; 1.64; 2.05 units on a scale
Malaria, Falciparum
Primary: Polymerase Chain Reaction Corrected Efficacy Defined as Adequate Clinical and Parasitological Response (ACPR) by Study Arm — 146; 151 Participants — p=0.38
Melanoma
Primary: Association of Baseline C11-AMT PET SUV Max Value With Objective Response — 6; 6; 1; 13 Participants — p=0.08
Human Immunodeficiency Virus (HIV)
Primary: Days to Viral Rebound During Analytical Treatment Interruption (ATI) — 18; 28 days
Lymphoid Leukemia · Acute Lymphoblastic Leukemia · Refractory Acute Lymphoblastic Leukemia
Primary: Complete Remission Rate (CR) + CR With Incomplete Recovery (CRi) — 30 Percent of participants
Cystic Fibrosis
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 1; 4; 2; 4 participants
Acute Rejection of Liver Transplant · Effects of Immunosuppressant Therapy
Primary: Proportion of Tolerant Patients Off SRL Therapy With Normal Liver Biochemistry and Graft Histology at 12 Months — 8 Participants
Diabetes Mellitus, Type 1
Primary: Active Treatment Period: C-peptide Area Under the Concentration-time Curve (AUC) Calculated From a 4 Hour Mixed Meal Tolerance Test (MMTT) at Week 52 — 0.43; 0.64…
Primary Biliary Cirrhosis
Primary: Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) at Week 8 — -26.06; -33.38; -41.42 percentage change from baseline — p== 0.2242
Glaucoma
Primary: Number of Patients That Achieve Target Intraocular Pressure Measured in mmHg — 8; 45; 22 Participants
Hip Osteoarthritis · Noninflammatory Degenerative Joint Disease · Avascular Necrosis
Primary: Stability Over a Period of Two Year Measured by Migration With Röntgen Stereophotogrammetric Analysis (RSA) — 3.15; 3.90 mm
Hypertension · Cardiovascular Risk Factor · Physical Activity
Primary: Change in Mean Office Systolic BP — 0.3; -4 mmHg